Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 224-232 , April 2009

A Pilot Study on the Role of Autoantibody Targeting the β1-Adrenergic Receptor in the Response to β-blocker Therapy for Congestive Heart Failure

  • Yuji Nagatomo, MD

      Affiliations

    • Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    • ,
  • Tsutomu Yoshikawa, MD

      Affiliations

    • Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    • Corresponding Author InformationReprint requests: Tsutomu Yoshikawa, MD, Cardiology Division, Department of Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160–8582, Japan.
    • ,
  • Takashi Kohno, MD

      Affiliations

    • Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    • ,
  • Akihiro Yoshizawa, MD

      Affiliations

    • Tokyo Dental College, Ichikawa General Hospital, Ichikawa, Japan
    • ,
  • Akiyasu Baba, MD

      Affiliations

    • Kitasato Institute Hospital, Tokyo, Japan
    • ,
  • Toshihisa Anzai, MD

      Affiliations

    • Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    • ,
  • Tomomi Meguro, MD

      Affiliations

    • Tokyo Electric Power Company Hospital, Tokyo, Japan
    • ,
  • Toru Satoh, MD

      Affiliations

    • Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan
    • ,
  • Satoshi Ogawa, MD

      Affiliations

    • Cardiology Division, Department of Medicine, Keio University School of Medicine, Tokyo, Japan

Received 26 January 2008 ,Revised 21 October 2008 ,Accepted 22 October 2008.

References 

  1. Magnusson Y, Marullo S, Hoyer S, Waagstein F, Andersson B, Vahlne A , et al. Mapping of a functional autoimmune epitope on the β1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest. 1990;86:1658–1663
  2. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect. Circulation. 1994;89:2760–2767
  3. Magnusson Y, Hjalmarson A, Hoebeke J. Beta1-adrenoceptor autoimmunity in cardiomyopathy. Int J Cardiol. 1996;54:137–141
  4. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human β1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation. 1999;99:649–654
  5. Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second extracellular loop of β1-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2001;37:418–424
  6. Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-β1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol. 1995;27:397–406
  7. Mobini R, Magnusson Y, Wallukat G, Viguier M, Hjalmarson A, Hoebeke J. Probing the immunological properties of the extracellular domains of the human β1-adrenoceptor. J Autoimmun. 1999;13:179–186
  8. Mobini R, Fu M, Wallukat G, Magnusson Y, Hjalmarson A, Hoebeke J. A monoclonal antibody directed against an autoimmune epitope on the human beta1-adrenergic receptor recognized in idiopathic dilated cardiomyopathy. Hybridoma. 2000;19:135–142
  9. Staudt A, Mobini R, Fu M, Grosse Y, Stangl V, Stangl K, et al. β1-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes. Eur J Pharm. 2001;423:115–119
  10. Podlowski S, Luther HP, Morwinski R, Muller J, Wallukat G. Agonistic anti-β1-adrenergic receptor autoantibodies from cardiomyopathy patients reduce the β1-adrenergic receptor expression in neonatal rat cardiomyocytes. Circulation. 1998;98:2470–2476
  11. Jahns R, Boivin V, Krapf T, Wallukat G, Boege F, Lohse MJ. Modulation of beta1-adrenoceptor activity by domain-specific antibodies and heart failure-associated autoantibodies. J Am Coll Cardiol. 2000;36:1280–1287
  12. Iwata M, Yoshikawa T, Baba A, Anzai T, Nakamura I, Wainai Y, et al. Autoimmunity against the second extracellular loop of β1-adrenergic receptors induces β-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res. 2001;88:578–586
  13. Staudt Y, Mobini R, Fu M, Felix SB, Kuhn JP, Staudt A. β1-Adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharm. 2003;466:1–6
  14. Christ T, Wettwer E, Dobrev D, Adolph E, Knaut M, Wallukat G, et al. Autoantibodies against the β1-adrenoceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol. 2001;33:1515–1525
  15. Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, et al. Direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. J Clin Invest. 2004;113:1419–1429
  16. Stork S, Boivin V, Horf R, Hein R, Lohse MJ, Angermann CE, et al. Stimulating autoantibodies directed against the cardiac β1-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J. 2006;152:697–704
  17. Fukuda Y, Miyoshi S, Tanimoto K, Oota K, Fujikura K, Iwata M, et al. Autoimmunity against the second extracellular loop of beta1-adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits. J Am Coll Cardiol. 2004;43:1090–1100
  18. Wallukat G, Muller J, Hetzer R. Specific removal of β1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy. N Engl J Med. 2002;347:1806
  19. The U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med. 1996;334:1349–1355
  20. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet. 1999;353:9–13
  21. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  22. The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651–1658
  23. Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the multicenter carvedilol heart failure dose assessment (MUCHA) trial. Am Heart J. 2004;147:324–330
  24. Yokota Y, Nomura H, Kawai H, Tsumura Y, Takeuchi Y, Kurozumi H, et al. Effects of long-term beta-blockade (metoprolol) therapy in patients with dilated cardiomyopathy. Jpn Circ J. 1991;55:343–355
  25. Kohno T, Yoshikawa T, Yoshizawa A, Nakamura I, Anzai T, Satoh T, et al. Carvedilol exerts more potent antiadrenergic effect than metoprolol in heart failure. Cardiovasc Drugs Ther. 2005;19:347–355
  26. Miao GB, Liu JC, Liu MB, Wu JL, Zhang G, Chang J, et al. Autoantibody against β1-adrenergic receptor and left ventricular remodeling changes in response to metoprolol treatment. Eur J Clin Invest. 2006;36:614–620
  27. Bond RA, Leff P, Johnson TD, Milano CA, Rockman HA, McMinn TR, et al. Physiological effects of inverse agonists in transgenic mice with myocardial overexpression of the beta 2-adrenoceptor. Nature. 1995;374:272–276
  28. Mialet Perez J, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, et al. β1-Adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med. 2003;9:1300–1305
  29. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, et al. A polymorphism within a conserved β1-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006;103:11288–11293
  30. Rochais F, Vilardaga JP, Nikolaev VO, Bunemann M, Lohse MJ, Engelhardt S. Real-time optical recording of beta1-adrenergic receptor activation reveals supersensitivity of the Arg389 variant to carvedilol. J Clin Invest. 2007;117:229–235
  31. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, et al. Beta1- and beta2-adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium. Circ Res. 1986;59:297–309
  32. Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis. Circulation. 1999;100:2210–2212
  33. Peter PS, Brady JE, Yan L, Chen W, Engelhardt S, Wang Y, et al. Inhibition of p38α MAPK rescues cardiomyopathy induced by oversexpressed β2-adrenergic receptor, but not β1-adrenergic receptor. J Clin Invest. 2007;117:1335–1343
  34. Liu H, Zhao R, Jiao X, Wang Y, Fu M. Relationship of myocardial remodeling to the genesis of serum autoantibodies to cardiac beta1-adrenoceptors and muscarinic type 2 acetylcholine receptors in rats. J Am Coll Cardiol. 2002;39:1866–1873

 Conflict of interest: none.

PII: S1071-9164(08)01051-8

doi: 10.1016/j.cardfail.2008.10.027

Journal of Cardiac Failure
Volume 15, Issue 3 , Pages 224-232 , April 2009

Article Tools

* Image Usage & Resolution